Koch Disruptive Technologies, Longliv Ventures and OurCrowd participated in the round, bringing Sight Diagnostics’ total funding to more than $124 million, according to a news release.
Tel Aviv, Israel-based Sight Diagnostics said the funding will support its commercial operations around the world while also advancing its R&D into the detection of new diseases, as well as the blood factors affecting the severity of COVID-19.
“This new investment will enable Sight to substantially expand our U.S. footprint and help usher in a new era of AI-driven diagnostics for a myriad of diseases and health conditions,” Sight Diagnostics CEO & co-founder Yossi Pollak said in the release. “We’re glad to have Koch Disruptive Technologies, OurCrowd and other esteemed investors join us on our mission to improve health systems and patient outcomes through developing fast, accurate and less painful diagnostics.”
Sight develops the OLO blood analyzer, which received FDA 510(k) clearance in December 2019 and is currently being deployed in frontline healthcare facilities outside the U.S. in the fight against COVID-19. The device automates the identification and counting of different blood cell types and anomalies.